DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5bf37m/shigella) has announced the addition of the "Shigella Infections (Shigellosis) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Anacor Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- GlycoVaxyn AG
- 1790GAHB Vaccine
- shigella vaccine
- shigella vaccine 1
- shigellosis [Shigella flexneri 2a] (whole cell) vaccine
- Small Molecule for Shigellosis
- Small Molecule to Inhibit Rns and VirF for Bacterial Infections
For more information visit http://www.researchandmarkets.com/research/5bf37m/shigella